“Merck and Eisai’s Cancer Drugs Fall Short in Improving Overall Survival in Late-Stage Trial: A Disappointing Outcome for the Pharmaceutical Industry”
Blog Post Article Merck and Eisai Cancer Drug Combination Fails Late-Stage Trial In a disappointing turn of events for patients with esophageal cancer, a late-stage trial testing the combination of Merck’s blockbuster drug Keytruda and Eisai’s cancer drug Lenvima with chemotherapy has failed to improve overall survival rates. The two pharmaceutical companies announced the results…